Navigation Links
CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Date:10/23/2007

Preclinical Studies of Valecor Platinum(TM) Coronary Stent System Indicate Positive Results and Improvements Compared to Market-Leading Bare Stent

BURLINGTON, Mass., Oct. 23 /PRNewswire/ -- CorNova, Inc. announced today that S. Eric Ryan, M.D., Chairman & CEO of CorNova, presented preliminary results of its recent preclinical studies for CorNova's Valecor Platinum(TM) Coronary Stent System at the TCT 2007 conference in Washington, D.C. The independently-conducted preclinical studies illustrated what CorNova believes to be meaningful improvements in neointimal proliferation, arterial injury, arterial inflammation, and reendothelialization when compared to a market-leading bare stent in rabbit and porcine models.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO )

Commenting on today's announcement, Dr. Ryan stated, "We are very pleased with the results from these preclinical studies of our Valecor Platinum(TM) Stent, which is designed to maximize biocompatibility while minimizing arterial injury, potentially providing both short and long-term benefits over current bare stent technology. We also believe our Valecor Platinum(TM) Stent may offer the potential of improving coronary stent performance without the need for drug-elution and the inherent risks presented by drug-eluting stents. The Company is proceeding with its efforts to receive CE Mark approval for the Valecor Platinum(TM) Stent and we currently expect to receive that approval in early 2008."

About CorNova

CorNova, Inc., founded in 2003, is a privately-held, development-stage company with an experienced international team of business, medical, and engineering professionals within the field of interventional cardiology. CorNova's business focus is to build value and opportunity through the utilization of the technologies, expertise, and resources of its international team an
'/>"/>

SOURCE CorNova, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli Lilly ... of its long-standing technology transfer program to increase the ... in 2003, the effort included Lilly donating manufacturing technology ... China , India ... South Africa – all MDR-TB ,hot spots., ...
(Date:10/27/2014)... 27, 2014 Research and Markets has ... 2014-2018" report to their offering. H1N1 ... a variant of the swine H1N1 virus, known as H1N1v ... nose, throat, and lungs. H1N1 virus is an RNA virus ... animal species such as humans, swine, birds, seals, and horses. ...
(Date:10/27/2014)... EAST TAUNTON, Mass. , Oct. 27, 2014 /PRNewswire/ ... the $15 billion global hip and knee replacement device market, ... and knee replacement technology at the American Association of ... the Sheraton Dallas Hotel in Dallas, Texas ... is a Bronze corporate partner of the organization. ...
Breaking Medicine Technology:Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 2Global H1N1 Vaccines Market 2014-2018: Key Vendors are AstraZeneca, GlaxoSmithKline, Novartis and Sanofi Pasteur 3OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 2OMNIlife science to Exhibit at American Association of Hip and Knee Surgeons 24th Annual Meeting in Dallas November 6-9 3
... Bulletin Board: GOVX ) announced today the publication ... its HIV/AIDS vaccine products. The article, titled "Phase 1 Safety ... Vaccines Expressing HIV-1 Virus-like Particles," will appear in the March ... Diseases . A PDF of the article is available at ...
... Inc., a leader in room temperature biostability technology, ... (IQT). IQT is the independent, strategic investment firm ... mission of the U.S. Intelligence Community. ... pioneered recent innovations in ambient storage of biological ...
Cached Medicine Technology:GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 2GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 3GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases 4Biomatrica Secures Strategic Investment from IQT 2Biomatrica Secures Strategic Investment from IQT 3
(Date:10/30/2014)... at least 2 years old to be covered by ... guidance exists other than the general recommendation by national ... least the first six months. , So what ... that motivated researchers at the University at Buffalo School ... patterns of American infants at 6 months and 12 ...
(Date:10/30/2014)... Timothy, InstaKNOT’s 4-year-old CEO, ... showing that you are never too young to give ... Tracey and Carl at the 2013 Santa Arriving By ... Beach Chamber of Commerce. Tracey gave Timothy a special ... wear his real fireman’s hat, and extending an offer ...
(Date:10/30/2014)... Five months after their expansion, the ... new branding and a website to accompany their recent ... Mepham’s promotion to name partner earlier this year, Hodgkinson ... Mepham’s name and better reflect their combined litigation expertise. ... decision to implement new branding reflects Hodgkinson Street Mepham’s ...
(Date:10/30/2014)... Reinberg HealthDay Reporter , WEDNESDAY, ... men with prostate cancer who also have certain heart problems ... a new study suggests. , , The therapy in question is ... to reduce levels of male hormones to prevent the growth ... current research, this hormone therapy was linked to triple the ...
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
Breaking Medicine News(10 mins):Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Hodgkinson Street Mepham Rebrands 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2
... Aug. 25 HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) a ... for the second quarter ended June 30, 2009. The company ... in prescription sales and pharmacy transfers. Gross margins increased 7.8% ... $396,271. , , "Consumers are increasingly switching ...
... FT. WASHINGTON, Pa., Aug. 25 The makers of ZYRTEC(R) ... announced the availability of two new allergy solutions to help ... Children,s ZYRTEC(R) PERFECT MEASURE(R) and ZYRTEC(R) Itchy Eye Drops are ... products. The company also announced the launch of AllergyCast, ...
... , CHICAGO, Aug. 25 Health care costs are ... according to Aon Consulting, the global human capital consulting organization of ... (NYSE: AOC ). , , ... more than 60 leading health care insurers, representing more than 100 million ...
... food has been detected in unusually high levels in ... condition pre-eclampsia. These results are important because they ... pre-eclampsia and may help scientists to understand the cause ... at the University of Leeds took blood samples from ...
... polyps, sessile serrated polyps (also called sessile serrated adenomas), ... polyps share molecular features with a subgroup of colon ... be precursors of cancer through a hyperplastic polyp to ... arise in the proximal colon. Sessile serrated polyps may ...
... that connective tissue growth factor (CCN2) plays a ... systems. Fibrosis is a scarring condition that is ... cell function and can cause organ dysfunction and ... liver is the activation of hepatic stellate cells ...
Cached Medicine News:Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 2Health News:HealthWarehouse.com, Inc. Announces Second Quarter Financial Results; Revenues Increase Significantly Over Second Quarter 2008 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 2Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 3Health News:Just in Time for Allergy Season, ZYRTEC(R) Provides New Solutions for Adults and Children 4Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 2Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 3Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 4Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 5Health News:Employers Face 10.5 Percent Health Care Cost Increases, Says Aon Consulting 6Health News:New link between pre-eclampsia and diet 2Health News:Reinterpretation of proximal colon polyps called hyperplastic in 2001 2
... The MultiBlot tray is specifically designed for ... used 10.16 x 13.34cm dot blot transfer ... dimensions as a standard microplate for compatibility ... accepts commercially available dot blot membranes without ...
... vacuum regulator, base with vacuum stage, porous ... assorted window gaskets, lid, instructions. The ... transfers DNA or RNA from an agarose ... generally requires only 90 min for transfer, ...
... Tank Blotting System. Designed ... Transfer up to three gels ... x 21.5cm. Includes and internal ... and safety cover with attached power ...
... 2 gel holder cassettes, 4 fiber pads, ... buffer chamber, lid with cables, and instructions. ... of Bio-Rad's modular mini electrophoresis system (see ... of mini gels. Its modular electrode assembly ...
Medicine Products: